Oncoinvent As
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Holding
- Established
- 2010-08-10
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oncoinvent.com
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Oncoinvent AS
- Target Recruit Count
- 114
- Registration Number
- NCT06504147
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇧🇪UZ Leuven, Leuven, Belgium
🇳🇴The Norwegian Radiumhospital, Oslo, Norway
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
Phase 1
Active, not recruiting
- Conditions
- Peritoneal CarcinomatosisOvarian Cancer
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Oncoinvent AS
- Target Recruit Count
- 49
- Registration Number
- NCT03732768
- Locations
- 🇳🇴
The Norwegian Radiumhospital, Oslo, Norway
🇪🇸Clínica Universidad de Navarra, Pamplona, Spain
🇧🇪UZ Leuven, Leuven, Belgium
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
Phase 1
Active, not recruiting
- Conditions
- Peritoneal CarcinomaColorectal Carcinoma
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Oncoinvent AS
- Target Recruit Count
- 67
- Registration Number
- NCT03732781
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
🇸🇪Akademiska, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath